BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells
about
Strategically targeting MYC in cancerAdvances in sarcoma diagnostics and treatmentFOXM1 in sarcoma: role in cell cycle, pluripotency genes and stem cell pathwaysaBETting therapeutic resistance by Wnt signalingBRD4 inhibition suppresses cell growth, migration and invasion of salivary adenoid cystic carcinoma.Oncopig Soft-Tissue Sarcomas Recapitulate Key Transcriptional Features of Human SarcomasThe bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo.BET inhibition as a new strategy for the treatment of gastric cancer.The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.Relationship Between P15 Gene Mutation and Formation and Metastasis of Malignant Osteosarcoma.Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance.The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood SarcomaLoss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanismsPhospho-BRD4: transcription plasticity and drug targeting.MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.MiR-24-BIM-Smac/DIABLO axis controls the sensitivity to doxorubicin treatment in osteosarcoma.Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics.Bisphosphonate-Functionalized Hydroxyapatite Nanoparticles for the Delivery of the Bromodomain Inhibitor JQ1 in the Treatment of Osteosarcoma.Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors.Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors.Kinome-wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics.Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.Nucleoside diphosphate kinase B promotes osteosarcoma proliferation through c-Myc.Small animal models for the study of bone sarcoma pathogenesis:characteristics, therapeutic interests and limitations.JQ1 affects BRD2-dependent and independent transcription regulation without disrupting H4-hyperacetylated chromatin statesIsocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1
P2860
Q26747745-575A7FB3-3DDC-4354-90E3-789F22F46208Q28069695-A47EBB56-56A3-4D24-BD37-C44517F7AC4FQ28076296-5DA068EB-28EC-4D0E-B9EC-6AF2C4DF1BCFQ28081557-3955FB35-E395-4B90-A848-FB690A5D500BQ33730555-BE19E541-43CC-4F1D-8F0B-8F34DEE18E92Q33752789-498F6E8F-B79B-4F0D-A265-E320CA3613B2Q33844624-EBC19BBA-DAB0-4549-AFC3-191BF870DDFCQ36040347-E6ABD63E-F3E9-462F-A4A2-0432E8BF7B65Q36169695-6A0E278A-552F-42D5-971A-9DBCC7B3BEBFQ36635978-99287606-1953-4A86-949E-B42AA799DAE0Q36862527-793A2649-EDDB-46A4-AA67-659D47294756Q36918007-967572C4-A379-4849-9BDE-0AE953E108CAQ37161750-CCBE626B-C23F-4365-AF51-5D64E442D65DQ37424187-36C85FB0-B4CA-4EEC-A3A1-9B25B229ACE2Q37718370-04BCB341-1F49-477C-8275-EE82BAAD4781Q38260084-B1AB38B4-9FC6-4899-BD61-40B469806705Q39024306-4C42EC4B-BB29-4E28-BF65-4563B8BF713EQ40041197-39AF9F84-95A5-4FB0-A538-210A26CA066CQ41215178-761B25F9-FFA0-4048-B458-1ED4AB99D115Q44988870-D59C69DD-F393-43E9-AB08-B2BEE2F5CA11Q46924536-1A23B0E7-9360-44B7-848B-61CEC65A5F64Q47098738-10679892-94AC-4F0F-BAD6-F52F08E08E60Q47272627-36133449-73A4-4F25-80B2-69FF74C2D317Q47708657-E56E75DC-F7BF-420F-A801-FF0A537634F5Q52671034-A9848E55-CCAF-4B0E-AFD5-60EEF72DFB6EQ54116955-3CF0142A-B74D-4B92-8719-7287979B42F7Q55033636-EDDFB03F-6FFB-4043-B935-1384D117A638Q57893466-B0C6ADE3-C71F-4EE8-86AA-B7A228F11A3FQ58728288-203B4DDA-8196-4378-A892-BD901AD07223
P2860
BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
BET inhibitors induce apoptosi ...... ors to kill osteosarcoma cells
@ast
BET inhibitors induce apoptosi ...... ors to kill osteosarcoma cells
@en
type
label
BET inhibitors induce apoptosi ...... ors to kill osteosarcoma cells
@ast
BET inhibitors induce apoptosi ...... ors to kill osteosarcoma cells
@en
prefLabel
BET inhibitors induce apoptosi ...... ors to kill osteosarcoma cells
@ast
BET inhibitors induce apoptosi ...... ors to kill osteosarcoma cells
@en
P2093
P2860
P50
P356
P1433
P1476
BET inhibitors induce apoptosi ...... ors to kill osteosarcoma cells
@en
P2093
Ankita Gupte
Emma K Baker
Mannu Walia
Nicole C Walsh
Scott Taylor
P2860
P2888
P356
10.1038/SREP10120
P407
P577
2015-05-06T00:00:00Z